Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path

The ENCORE study's results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potential to benefit patients with Mycobacterium avium complex lung infections.
Open original source